PeptiDream Announces License of PeptiDream's Peptide Discovery Platform System (PDPS) Technology to Novartis

TOKYO--(BUSINESS WIRE)-- PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO: 4587) announced today that Swiss-based Novartis has exercised its option under their 2012 Strategic Alliance Agreement to obtain a nonexclusive license to PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Under the terms of the Technology License Agreement, PeptiDream will receive multi-stage upfront technology access payments, and will be eligible to receive development milestones and royalties on future sales of products that arise from use of the PDPS technology.

Comments from Kiichi Kubota, CEO of PeptiDream Inc.

“We are delighted with Novartis’s decision to internalize the PDPS technology under our 2012 Strategic Alliance Agreement, and this exercise further validates our PDPS technology as one of the best hit-finding/discovery platforms. The license agreement will significantly contribute to PeptiDream’s revenue both in the short term and has the potential to generate significant revenues long into the future.”

About PeptiDream Inc.

PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS) , a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics.

Enquiries:
PeptiDream Inc.
Patrick C Reid, +81-3-5790-9991 (Tokyo)
[email protected]

Source: PeptiDream Inc.

You May Also Be Interested In

• Accounting for the Role of Gender is Critical to Maximizing Philanthropic Impact, According to Study
• IMAX® and CineNOVA Launch Partnership With Four New IMAX Locations Across Turkey
• ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update